Biocon Biologics Denies Bribery Allegations

  • Posted by: Biocon Biologics

COMPANY STATEMENT

Bengaluru, Karnataka, India, June 21, 2022

“We deny the bribery allegations made in certain media stories. All our product approvals are legitimate and backed by science and clinical data. Our bAspart is approved in Europe and many other countries. We follow due regulatory process for all our product approvals by DCGI. The entire application process in India is online and all meeting minutes are in public domain. We are co-operating with the investigation agency.”

– Biocon Biologics, Spokesperson

Author: Biocon Biologics
Share